What is HC Wainwright’s Estimate for Altimmune Q2 Earnings?

Altimmune, Inc. (NASDAQ:ALT) – Investment analysts at HC Wainwright decreased their Q2 2025 EPS estimates for shares of Altimmune in a report issued on Monday, March 3rd. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.34) per share for the quarter, down from their previous forecast of ($0.33). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Altimmune’s FY2025 earnings at ($1.34) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.40) EPS, FY2027 earnings at ($1.40) EPS and FY2028 earnings at ($0.14) EPS.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million.

A number of other analysts also recently weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target for the company. William Blair assumed coverage on Altimmune in a research note on Friday, February 28th. They set a “market perform” rating on the stock. Finally, UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.83.

Altimmune Stock Down 4.0 %

Shares of NASDAQ:ALT opened at $5.72 on Thursday. Altimmune has a 52-week low of $5.28 and a 52-week high of $11.77. The company has a 50 day moving average of $6.74 and a two-hundred day moving average of $7.18. The company has a market capitalization of $440.52 million, a price-to-earnings ratio of -3.69 and a beta of 0.87.

Institutional Investors Weigh In On Altimmune

A number of hedge funds have recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. lifted its stake in Altimmune by 356.8% in the fourth quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock valued at $79,000 after buying an additional 8,470 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Altimmune by 16.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,392 shares of the company’s stock valued at $666,000 after purchasing an additional 13,126 shares in the last quarter. Two Sigma Investments LP grew its holdings in Altimmune by 33.2% during the fourth quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock worth $4,364,000 after acquiring an additional 151,001 shares during the period. Rafferty Asset Management LLC grew its holdings in Altimmune by 1.3% during the fourth quarter. Rafferty Asset Management LLC now owns 157,750 shares of the company’s stock worth $1,137,000 after acquiring an additional 1,964 shares during the period. Finally, ProShare Advisors LLC grew its holdings in Altimmune by 74.1% during the fourth quarter. ProShare Advisors LLC now owns 23,371 shares of the company’s stock worth $169,000 after acquiring an additional 9,950 shares during the period. 78.05% of the stock is currently owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.